Researchers report what may be the first case of Charcot-Marie-Tooth (CMT) type 1 neuropathy being diagnosed in a 55-year-old patient after she was given standard care for advanced breast cancer. Doctors later found the woman had a family history of CMT, and the scientists speculate that the neuropathy was triggered…
Being overweight does not worsen nerve function in people with Charcot–Marie–Tooth Disease type 1A (CMT1A), but it may lead to more pain and less muscle strength in lower extremities, a study reports. Researchers published the study in the Journal of Clinical Neurophysiology. Its title is “Charcot–Marie–Tooth Disease Type 1A: Influence of Body…
Eight genes in the skin of patients with Charcot-Marie-Tooth disease correlated with the severity and progression of the disorder, a study reports. The research, which applied to Charcot-Marie-Tooth disease type 1a (CMT1a), suggested that the genes could be used as biomarkers of treatments’ effectiveness, including in clinical trials. Titled “Biomarkers predict outcome in Charcot- Marie-Tooth disease 1A,” the study…
An amendment in the protocol of two ongoing Phase 3 studies – the PLEO-CMT and PLEO-CMT-FU – testing the investigational drug PXT3003 in adults with Charcot-Marie-Tooth disease type 1A (CMT1A) was introduced to address stability issues with the drug’s highest dose arm, Pharnext announced. In the PLEO-CMT study (NCT02579759),…
Get regular updates to your inbox.